NCT02223078已完成2 期
Phase II, Randomised, Double-blind, Placebo-controlled, Parallel Group, Two Centre Study to Determine the Effect of G17DT on Plasma Gastrin Levels in Patients With Colorectal Cancer.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 1
- 主要终点
- Antibody Levels
研究概览
简要总结
Pancreatic, gastric, and colorectal cancers have all been shown to overexpress the gastrin gene and to be sensitive to the trophic effects of the gastrin in animal models. The hypothesis of this study is that G17DT will elicit specific and high-affinity antibodies that will bind gastrin-17, thus preventing the trophic activity of cancer cells.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with histologically confirmed colorectal carcinoma for whom no other anti-cancer treatment was anticipated during the three month period of study.
- •Patients taking a proton pump inhibitor at a fixed daily dose which had remained unchanged for at least six weeks preceding screening and was not anticipated to change during the study.
- •Proton pump inhibitor compliance of ~70% (to be measured between screening and baseline (week 0)).
- •Male or female patients from 18 to 65 years of age.
- •Patients with a life expectancy of over three months.
- •World Health Organisation (WHO) Performance Status of 0 to
- •Written informed consent given.
排除标准
- •Patients in receipt of histamine H2-receptor (H2 receptor) antagonists or any other antacid therapy, other than a proton pump inhibitor at a stable dose.
- •Patients with any other factor likely to alter intra-gastric acidity e.g. previous gastric surgery, including vagotomy or anatomically abnormal upper gastrointestinal tract.
- •History of other malignant disease within the previous five years, except non- melanomatous skin cancer or in situ carcinoma of the uterine cervix.
- •Previous use within the last four weeks, concomitant use or anticipated use in the period of the study of radiotherapy or chemotherapy.
- •Concomitant use of immunosuppressants, including systemic (i .e. oral or injected) corticosteroids.
- •Females who were pregnant, planning to become pregnant or lactating. Women, who in the opinion of the investigator were of child bearing potential, were to have a negative pregnancy test before study drug administration.
- •Patients taking part in another study involving an investigational or licensed drug or device in the three months preceding enrolment or during the study.
- •Previous G 17DT treatment.
- •Haematological indicators:
- •Haemoglobin <10.0 g/dL White blood cell count <4.0 x 109/L Platelets < 100 x 1 09/L
结局指标
主要结局
Antibody Levels
时间窗: 12 weeks
Assess effects of gastrin-17 antibodies in response to G17DT immunization.
次要结局
- pharmacodynamic(12 weeks)
- Number of Participants with Serious and Non-Serious Adverse Events(12 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Study to Assess Safety and Tolerability of G17DT in Patients With Colorectal Adenocarcinoma.Colorectal CancerNCT02181465Cancer Advances Inc.11
Unknown
不适用
Usefulness of Serum Pepsinogen and Gastrin as the Predictive Biomarker of Atrophic Gastritis, Intestinal Metaplasia and Gastric Cancer in KoreaAtrophic GastritisNCT02184910Yonsei University108
Unknown
不适用
Cremona Population-Based Gastric Tumors RegistryGastric CancerNCT01662739Medicina e Arte Onlus1,000
Unknown
不适用
Clinical Study of Gastric Cancer, Colorectal Cancer and Bladder Cancer Based on Liquid BiopsyColorectal CancerBladder CancerGastric CancerNCT04385316The First Affiliated Hospital with Nanjing Medical University3
招募中
不适用
Gastric Cancer Organoids in the Screening of Neoadjuvant DrugsOrganoidNeoadjuvant TherapyGastric CancerNCT06196554Dong Bing Zhao40